Search - tctmd.com

Displaying 781 - 800 of 991

Sort: Relevancy | Date

News Daily News

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Yael L. Maxwell

February 26, 2014

News Daily News

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Yael L. Maxwell

February 17, 2014

News Daily News

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

February 12, 2014

News Daily News

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

January 09, 2014

News Daily News

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

January 01, 2014

News Daily News

Meta Análisis: Comparados con los SMD, los SLF de Última Generación son Seguros y Eficaces contra los cuadros de STEMI

January 01, 2014

News Daily News

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

December 30, 2013

Presentation TCT 2013

Yes – There are No Substantial Clinical Trials Proving Safety or Efficacy!

Presenter: Sigmund Silber

October 31, 2013

Presentation TCT 2013

PEPCAD-China ISR Trial: 9-Month Angiographic and 1-Year Clinical Results

Presenter: Junbo Ge

October 31, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

News Conference News TCT 2013

LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD

October 30, 2013

Presentation TCT 2013

TCT-39. 12-Month Angiographic and Clinical Results of the ReZolve® Sirolimus-Eluting Bioresorbable Coronary Scaffold: The RESTORE trial

Presenter: Ricardo Costa

October 29, 2013

Presentation TCT 2013

TCT-32. First Report of the Four Year Clinical Results of The ABSORB Trial Evaluating the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Patients...

Presenter: Bernard Chevalier

October 29, 2013

Presentation TCT 2013

The Promus Element Everolimus-Eluting Stent: Design Considerations and Clinical Trial Results (from PLATINUM to HOST-ASSURE)

Presenter: Hyo-Soo Kim

October 28, 2013

Presentation TCT 2013

From Xience V to Prime to Xpedition: Stent Design Evolution and Clinical Trial Results (SPIRIT and Others)

Presenter: James Hermiller Jr

October 28, 2013

Presentation TCT 2013

Synthesis of the ISAR Clinical Trials Comparing Different Stents in Different Settings

Presenter: Adnan Kastrati

October 28, 2013

Presentation TCT 2013

Synthesis of Clinical Trials with the Nobori Stent

Presenter: Takeshi Kimura

October 28, 2013

Presentation TCT 2013

Synthesis of Clinical Trials with the Biomatrix Stent

Presenter: Stephan Windecker

October 28, 2013

Presentation TCT 2013

Insights from the TWENTE Series of Clinical Trials: Past, Present, and Future

Presenter: Clemens von Birgelen

October 28, 2013

Presentation TCT 2013

Insights from the SORT-OUT Series of Clinical Trials: Past, Present, and Future

Presenter: Lisette Okkels Jensen

October 28, 2013

Advertisement

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

Meta Análisis: Comparados con los SMD, los SLF de Última Generación son Seguros y Eficaces contra los cuadros de STEMI

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

Yes – There are No Substantial Clinical Trials Proving Safety or Efficacy!

PEPCAD-China ISR Trial: 9-Month Angiographic and 1-Year Clinical Results

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD

TCT-39. 12-Month Angiographic and Clinical Results of the ReZolve® Sirolimus-Eluting Bioresorbable Coronary Scaffold: The RESTORE trial

TCT-32. First Report of the Four Year Clinical Results of The ABSORB Trial Evaluating the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Patients...

The Promus Element Everolimus-Eluting Stent: Design Considerations and Clinical Trial Results (from PLATINUM to HOST-ASSURE)

From Xience V to Prime to Xpedition: Stent Design Evolution and Clinical Trial Results (SPIRIT and Others)

Synthesis of the ISAR Clinical Trials Comparing Different Stents in Different Settings

Synthesis of Clinical Trials with the Nobori Stent

Synthesis of Clinical Trials with the Biomatrix Stent

Insights from the TWENTE Series of Clinical Trials: Past, Present, and Future

Insights from the SORT-OUT Series of Clinical Trials: Past, Present, and Future

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content